de la Fuente-Fernández Raúl, Stoessl A Jon
Pacific Parkinson's Research Centre, University of British Columbia, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5.
Trends Neurosci. 2002 Jun;25(6):302-6. doi: 10.1016/s0166-2236(02)02181-1.
The biochemical bases of the placebo effect are still incompletely known. We show here that the placebo effect in Parkinson's disease is due, at least in part, to the release of dopamine in the striatum. We propose that the placebo effect might be related to reward mechanisms. The expectation of reward (i.e. clinical benefit) seems to be particularly relevant. According to this theory, brain dopamine release could be a common biochemical substrate for the placebo effect encountered in other medical conditions, such as pain and depression. Other neurotransmitters or neuropeptides, however, are also likely to be involved in mediating the placebo effect (e.g. opioids in pain disorders, serotonin in depression).
安慰剂效应的生化基础仍未完全明确。我们在此表明,帕金森病中的安慰剂效应至少部分归因于纹状体中多巴胺的释放。我们提出,安慰剂效应可能与奖赏机制有关。对奖赏(即临床益处)的期望似乎尤为重要。根据这一理论,脑内多巴胺释放可能是其他医学病症(如疼痛和抑郁症)中出现的安慰剂效应的共同生化底物。然而,其他神经递质或神经肽也可能参与介导安慰剂效应(例如疼痛病症中的阿片类物质、抑郁症中的血清素)。